OMA Logo

Welcome to the OMA Blog

The Obesity Medicine Association Blog is the leading industry hub for obesity medicine. Find the latest research, expert insights, and practical tips to tackle the multifaceted disease of obesity. Hear from OMA Outreach Committee members, OMA Board members, and more to gain a deeper understanding of the complex factors influencing obesity and explore innovative approaches to prevention, treatment, and long-term management. Join a community of healthcare professionals, researchers, and individuals passionate about combating obesity.

2024 Award Winners Blog Image

Obesity Medicine Association Announces the 2024 OMA Award Winners

The Obesity Medicine Association (OMA) announced its 2024 Award Winners at the recent Obesity Medicine 2024 conference in Denver, CO this April. ABOM Candidate of the Year Award Presented to the OMA member who scored the highest on the American Board of Obesity Medicine Certification Examination Recipient: Joseph Brewster, MD The Steelman-Seim Educator Award for Excellence in Academics For excellence in academics Recipient: Sylvia Gonsahn-Bollie, MD, DABOM, FOMA Dr.

Continue reading
Obesity Medicine Association logo

Obesity Management Foundations for the Primary Care Clinician

Collaborative course available from the AANP and the OMA.

Continue reading
two doctors standing next to each other holding clipboards

Leading Obesity Expert Organizations Release Statement to Patients on Compounded GLP-1 Alternatives

Today, there's renewed optimism due to the emergence of GLP1-based drug therapies like Wegovy (semaglutide) and Zepbound (tirzepatide), which demonstrate remarkable effectiveness for weight and health. Unfortunately, many of the available alternatives, like compounded versions of semaglutide and tirzepatide, are not what they are advertised to be. These companies stated that they do not sell the active ingredient to compounding pharmacies, and substances made or distributed by compounding pharmacies or other healthcare practitioners that claim to be semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) have not been reviewed by the FDA for safety, quality, or efficacy. For more information, see the following details: Compounded peptides: An Obesity Medicine Association Position Statement - ScienceDirect | Obesity Medicine Association Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA Compounding and the FDA: Questions and Answers | FDA Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide) | Eli Lilly and Company Responsible Use Letter | Novo Nordisk Things You Should Know About Compounded Anti-Obesity (AOM) Medications | Obesity Medicine Association

Continue reading
Group of Doctors and Nurses

Country’s Leading Obesity Expert Organizations Issue a Statement on the Full Results of the SELECT Study

The recent results of the SELECT Study published in the New England Journal of Medicine provide invaluable insights into the complex disease of obesity. The report has prompted several of the country’s leading obesity expert organizations, the Obesity Action Coalition (OAC), the Obesity Medicine Association (OMA), The Obesity Society (TOS), the American Society for Metabolic & Bariatric Surgery (ASMBS), and the STOP Obesity Alliance (STOP), to join together in issuing the following statement:

Continue reading
Graphic with the background split into half orange and half gray, with a headshot of Jennifer Seger on the right and text on the left reading: OMA Member Highlight, Jennifer Seger MD, FOMA with the OMA logo in the bottom right corner

September OMA Member Highlight

Jennifer Seger, MD, FOMA became a fellow of the OMA in 2016. Read her full interview below to learn more about Dr. Seger and her…

Continue reading
Image of San Antonio, Texas skyline with a teal overlay and the Overcoming Obesity 2023 conference logo at the top center. Below the logo is the text: schedule announced. Below that is the text: Oct 25-29, San Antonio, TX, up to 30 CME/CE

Overcoming Obesity 2023 – Schedule Announcement  

The agenda for Overcoming Obesity 2023 is now available to view! The Overcoming Obesity 2023 conference in San Antonio, TX, Oct 25-29 is the perfect…

Continue reading
FCON23 Featured Speaker Announcement Blog Image

Overcoming Obesity 2023 Featured Speaker Announced

Join OMA this October 25-29 in San Antonio, TX for Overcoming Obesity 2023. This conference is the perfect opportunity to network with fellow obesity medicine…

Continue reading
OMA Member Highlight graphic image: half orange, half gray with a headshot of Dr.Jerome Puryear. To the left of the image is the text: OMA Member Highlight, Jerome Puryear Jr. MD, DABOM with the OMA logo in the bottom right corner

August OMA Member Highlight

Jerome Puryear, Jr., MD, DABOM, became an OMA member in 2019 and has made a great impact in his time here. He is an active…

Continue reading
Image of Dr. Ethan Lazarus speaking in front of an audience in a conference room, with a presentation on the screen next to him

2023 Annual Meeting of the American Medical Association (AMA) House of Delegates Report

Ethan Lazarus, MD, FOMA (Immediate Past-President of the OMA) attended the Annual AMA Meeting as the OMA delegate and Anthony Auriemma, MD, JD (Trustee, OMA…

Continue reading

Showing 1-9 of 16 results

1 2